First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer

Last updated: March 18, 2025
Sponsor: Quanta Medical
Overall Status: Active - Recruiting

Phase

N/A

Condition

Breast Reconstruction

Treatment

MATTISSE TEC

Clinical Study ID

NCT05460780
3121_MATFIH22
  • Ages > 18
  • Female

Study Summary

This study is a first in human, two-stage single arm non-comparative study of safety and performance.

The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering chamber.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Criteria related to pathology:

  • Female patient over 18 Years old

  • Patient who required autologous breast reconstruction:

  • Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer

  • Breast reconstruction after unilateral preventive total mastectomy

  • or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation

  • or conversion from implant-based to autologous reconstruction: Patient who had a breast implant during a previous reconstruction after total mastectomy for cancer, and who needs to change it.

  • For patient with active cancer: Patient with early-stage cancer (stage 0, I or II, with tumor size < 50mm, without lymph-node involvement) needing oncological management that does not required radiotherapy after surgery on the breast area or on the flap donor site

  • Patient who required Nipple sparing (NSM) or Skin sparing mastectomy (SSM) with a unique surgical approach (same for mastectomy and implant) insertion; or implant removal for patient undergoing autologous conversion, or expender removal for patient undergoing differed reconstruction.

  • Autologous reconstruction using Lateral Intercostal Perforator (LICAP) flap or an intercostal thoracic artery perforation flap (LTAP) if oncological conditions do not allow for LICAP harvesting.

  • Patient medically fit for surgery without significant comorbidities

  • Breast cup-size less than D

  • Body mass index >20 kg/m2 or patient for whom sufficient flap volume is expected according to surgeon's assessment

  • Adequate hematopoietic functions

Criteria related to population:

  • Subjects who have given free, informed and written consent to participate in the study;

  • Patient able to answer questionnaires, able to communicate in the language of the study country;

  • Subjects affiliated to a social security schema or entitled to a social security scheme.

Non-inclusion Criteria:

Pathology related criteria:

  • Patient undergoing bilateral reconstruction

  • Patient undergoing bilateral preventive mastectomy

  • Patient undergoing simultaneous contralateral breast reduction, mastopexy, and augmentation

  • Previous history of radiotherapy on the breast area or on the flap donor site

  • Previous history of breast or axillary surgery that does not allow fat flap dissection

  • Presence of pacemaker or metallic prosthesis making patient unsuitable for MRI

  • Body mass index >30 kg/m2

  • Taking medication for weight loss at the time of inclusion visit

  • Presence of major medical conditions that may compromise patient's health and healing

  • Diabetes and a history of gestational diabetes

  • Active smoking

  • Microangiopathy, Vascular history and all systemic disease (systemic Raynaud's disease)

  • Patient with intertrigo or infection or alteration of the surgical site confirmed pre-operatively by clinical examination

  • Allergy to anesthetics or contrast media

  • Immunocompromised patient (HIV) or patient used immunosuppressants

Population related criteria

  • Pregnant patient

  • or breastfeeding patient or woman who has nursed a child three months within inclusion

  • Participation in a clinical trial in the 3 months prior to the initial visit

  • Predicted unavailability during study.

  • Patient deprived of liberty or under guardianship.

  • Patient unable to give consent

Medical device related criteria

  • Allergy to any of the components of the medical device.

EXCLUSION CRITERIA

  • Positive or suspicious extemporaneous sentinel node biopsy

  • Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler

  • Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: MATTISSE TEC
Phase:
Study Start date:
July 01, 2022
Estimated Completion Date:
December 31, 2028

Connect with a study center

  • Hospital of Lille

    Lille, Nord 59000
    France

    Active - Recruiting

  • CHU de Strasbourg

    Strasbourg, 67091
    France

    Active - Recruiting

  • Institute of Clinical Oncology

    Tbilissi, 0159
    Georgia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.